Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 May;14(5):388-96.
doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Glenda E Gray  1 , Zoe Moodie  2 , Barbara Metch  2 , Peter B Gilbert  2 , Linda-Gail Bekker  3 , Gavin Churchyard  4 , Maphoshane Nchabeleng  5 , Koleka Mlisana  6 , Fatima Laher  7 , Surita Roux  3 , Kathryn Mngadi  6 , Craig Innes  4 , Matsontso Mathebula  5 , Mary Allen  8 , M Julie McElrath  2 , Michael Robertson  9 , James Kublin  2 , Lawrence Corey  2 ; HVTN 503/Phambili study team
Collaborators, Affiliations
Clinical Trial

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Glenda E Gray et al. Lancet Infect Dis. 2014 May.

Abstract

Background: The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Americas, Caribbean, and Australia) were met. Here we report long-term follow-up data.

Methods: HVTN 503/Phambili was a double-blind, placebo-controlled, randomised trial that recruited HIV-1 uninfected, sexually active adults aged 18-35 years from five sites in South Africa. Eligible participants were randomly assigned (1:1) by computer-generated random numbers to either vaccine or placebo, stratified by site and sex. Cox proportional hazards models were used to estimate HIV-1 infection in the modified intention-to-treat cohort, all of whom were unmasked early in follow-up. The trial is registered with ClinicalTrials.gov, number NCT00413725 and the South African National Health Research Database, number DOH-27-0207-1539.

Findings: Between Jan 24, 2007, and Sept 19, 2007, 801 participants (26·7%) of a planned 3000 were randomly assigned (400 to vaccine, 401 to placebo); 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections. At a median follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared with 37 placebo recipients (9%; adjusted HR 1·70, 95% CI 1·13-2·55; p=0·01). Risk for HIV-1 infection did not differ according to the number of vaccinations received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus. Differences in risk behaviour at baseline or during the study, or annualised dropout rate (7·7% [95% CI 6·2-9·5] for vaccine recipients vs 8·8% [7·1-10·7] for placebo recipients; p=0·40) are unlikely explanations for the increased rate of HIV-1 infections seen in vaccine recipients.

Interpretation: The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism. We caution against further use of the Ad5 vector for HIV vaccines.

Funding: National Institute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Trial profile
Abbreviations: MITT – modified intent-to-treat; p-yrs – person years; FU – follow-up
Figure 2
Figure 2
a. Cumulative HIV-1 incidence curves for vaccine and placebo groups for main Phambili study (excluding sub-study) b. Cumulative HIV-1 incidence curves for vaccine and placebo groups including additional follow-up from follow-up study
Figure 2
Figure 2
a. Cumulative HIV-1 incidence curves for vaccine and placebo groups for main Phambili study (excluding sub-study) b. Cumulative HIV-1 incidence curves for vaccine and placebo groups including additional follow-up from follow-up study
See this image and copyright information in PMC

Comment in

  • Phambili: moving forward without the blindfold.
    Michael NL, Robb ML. Michael NL, et al. Lancet Infect Dis. 2014 May;14(5):361-2. doi: 10.1016/S1473-3099(14)70029-5. Epub 2014 Feb 20. Lancet Infect Dis. 2014. PMID: 24560542 No abstract available.

References

    1. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010 Sep;5(5):386–390. Review. PubMed PMID: 20978378; PubMed Central PMCID: PMC2967414. - PMC - PubMed
    1. Sheets RL, Stein J, Bailer RT, et al. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. J Immunotoxicol. 2008 Jul;5(3):315–335. PubMed PMID: 18830892; PubMed Central PMCID: PMC2777703. - PMC - PubMed
    1. Liu J, Ewald BA, Lynch DM, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol. 2008 May;82(10):4844–4852. Epub 2008 Mar 12. PubMed PMID: 18337575; PubMed Central PMCID: PMC2346755. - PMC - PubMed
    1. Barratt-Boyes SM, Soloff AC, Gao W, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J Gen Virol. 2006 Jan;87(Pt 1):139–149. PubMed PMID: 16361426. - PubMed
    1. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicitdurable cellular and humoral immune responses in nonhuman primates. J Virol. 2005 May;79(10):6516–6522. PubMed PMID: 15858035; PubMed Central PMCID: PMC1091731. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data